查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
嗜酸性粒细胞食道市场报告：2030 年趋势、预测与竞争分析
市场调查报告书
商品编码
1356925

嗜酸性粒细胞食道市场报告：2030 年趋势、预测与竞争分析

Eosinophilic Esophagitis Market Report: Trends, Forecast and Competitive Analysis to 2030
出版日期: | 出版商: Lucintel | 英文 150 Pages | 商品交期: 3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

嗜酸性粒细胞粒细胞性食道的趋势与预测

预计到 2030 年，全球嗜酸性粒细胞食道市场预计将达到 4 亿美元，2024 年至 2030 年年复合成长率为 15.6%。这个市场的主要驱动因素是人们对嗜酸性粒细胞食道的认识不断提高、食物和环境过敏病例不断增加，以及对先进诊断设备的需求不断增长，以早期发现和更好地监测该疾病。全球嗜酸性粒细胞食道市场前景广阔，医院、零售药局、网路药局市场蕴藏商机。

嗜酸性粒细胞粒细胞性食道市场洞察

  • Lucintel 预测，质子帮浦抑制剂预计将在预测期内达到最高成长，因为它们主要用于抑制胃酸分泌。
  • 预计医院在预测期内将出现最高成长。
  • 预计北美地区在预测期内将出现最高的成长。

本报告回答了 11 个关键问题：

  • Q.1. 细分市场中最有前途和高成长的机会是什么？
  • Q.2.哪个细分市场将以更快的速度成长？为什么？
  • Q.3.您认为哪些地区未来会出现更快的成长？为什么？
  • Q.4. 影响市场动态的主要因素有哪些？市场的主要挑战和商业风险是什么？
  • Q.5. 这个市场的商业风险和竞争威胁是什么？
  • Q.6.这个市场有哪些新趋势？为什么？
  • Q.7.市场客户需求有何改变？
  • Q.8. 该市场有哪些新发展以及哪些公司处于领先地位？
  • Q.9.这个市场的主要企业有哪些？主要企业采取哪些策略配合措施来发展业务？
  • Q.10. 该市场上的竞争产品有哪些？由于材料或产品替代而导致市场占有率下降的威胁有多大？
  • Q.11.过去年度发生了哪些併购事件，对产业产生了哪些影响？

目录

第1章执行摘要

第2章全球嗜酸性粒细胞食道市场：市场动态

  • 简介、背景、分类
  • 供应链
  • 产业驱动因素与挑战

第3章2018-2030年市场趋势及预测分析

  • 宏观经济趋势（2018-2023）与预测（2024-2030）
  • 全球嗜酸性粒细胞食道市场趋势（2018-2023）与预测（2024-2030）
  • 按药物类型分類的全球嗜酸性粒细胞粒细胞性食道市场
    • 皮质类固醇
    • 质子帮浦抑制剂
    • 后期管线药物
  • 按最终用途分類的全球嗜酸性粒细胞细胞性食道市场
    • 医院
    • 零售药房
    • 网路药房

第4章2018-2030年分地区市场趋势及预测分析

  • 全球嗜酸性粒细胞食道市场区域分布
  • 北美嗜酸性粒细胞食道市场
  • 欧洲嗜酸性粒细胞粒细胞性食道市场
  • 亚太地区嗜酸性粒细胞食道市场
  • 其他区域嗜酸性粒细胞食道市场

第5章竞争分析

  • 产品系列分析
  • 营运整合
  • 波特五力分析

第6章成长机会与策略分析

  • 成长机会分析
    • 按药物类型分類的全球嗜酸性粒细胞细胞性食道市场成长机会
    • 全球嗜酸性粒细胞食道市场成长机会（依最终用途）
    • 全球嗜酸性粒细胞食道市场成长机会（按地区）
  • 全球嗜酸性粒细胞食道市场的新趋势
  • 战略分析
    • 新产品开发
    • 全球嗜酸性粒细胞食道市场的产能扩张
    • 全球嗜酸性粒细胞食道市场的合併、收购与合资企业
    • 认证和许可

第7章主要企业概况

  • Ellodi Pharmaceuticals
  • EsoCap
  • GlaxoSmithKline
  • Teva Pharmaceutical Industries
  • Cipla
  • Sun Pharmaceutical Industries
  • AstraZeneca
  • Sanofi
  • Arena Pharmaceuticals
  • Takeda Pharmaceutical
简介目录

Eosinophilic Esophagitis Trends and Forecast

The future of the global eosinophilic esophagitis market looks promising with opportunities in the hospital, retail pharmacy, and online pharmacy markets. The global eosinophilic esophagitis market is expected to reach an estimated $0.4 billion by 2030 with a CAGR of 15.6% from 2024 to 2030. The major drivers for this market are rising awareness of eosinophilic esophagitis, growing cases of food and environmental allergies, and expanding need for advanced diagnostic equipment for disease early identification and better monitoring.

A more than 150-page report is developed to help in your business decisions.

Eosinophilic Esophagitis by Segment

The study includes a forecast for the global eosinophilic esophagitis by drug type, end use, and region.

Eosinophilic Esophagitis Market by Drug Type [Shipment Analysis by Value from 2018 to 2030]:

  • Corticosteroids
  • Proton Pump Inhibitor
  • Late Stage Pipeline Drugs

Eosinophilic Esophagitis Market by End Use [Shipment Analysis by Value from 2018 to 2030]:

  • Hospital
  • Retail Pharmacies
  • Online Pharmacies

Eosinophilic Esophagitis Market by Region [Shipment Analysis by Value from 2018 to 2030]:

  • North America
  • Europe
  • Asia Pacific
  • The Rest of the World

List of Eosinophilic Esophagitis Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies eosinophilic esophagitis companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the eosinophilic esophagitis companies profiled in this report include-

  • Ellodi Pharmaceuticals
  • EsoCap
  • GlaxoSmithKline
  • Teva Pharmaceutical Industries
  • Cipla
  • Sun Pharmaceutical Industries
  • AstraZeneca
  • Sanofi
  • Arena Pharmaceuticals
  • Takeda Pharmaceutical

Eosinophilic Esophagitis Market Insights

  • Lucintel forecasts that proton pump inhibitor is expected to witness highest growth over the forecast period due to its substantial application to reduce stomach acid production.
  • Hospital is expected to witness highest growth over the forecast period.
  • North America is expected to witness highest growth over the forecast period.

Features of the Global Eosinophilic Esophagitis Market

  • Market Size Estimates: Eosinophilic esophagitis market size estimation in terms of value ($B).
  • Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
  • Segmentation Analysis: Eosinophilic esophagitis market size by drug type, end use, and region. in terms of value ($B).
  • Regional Analysis: Eosinophilic esophagitis market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
  • Growth Opportunities: Analysis of growth opportunities in different drug types, end uses, and region.s for the eosinophilic esophagitis market.
  • Strategic Analysis: This includes M&A, new product development, and competitive landscape of the eosinophilic esophagitis market.
  • Analysis of competitive intensity of the industry based on Porter's Five Forces model.

FAQ

Q.1. What is the eosinophilic esophagitis market size?

Answer: The global eosinophilic esophagitis market is expected to reach an estimated $0.4 billion by 2030.

Q.2. What is the growth forecast for eosinophilic esophagitis market?

Answer: The global eosinophilic esophagitis market is expected to grow with a CAGR of 15.6% from 2024 to 2030.

Q.3. What are the major drivers influencing the growth of the eosinophilic esophagitis market?

Answer: The major drivers for this market are rising awareness of eosinophilic esophagitis, growing cases of food and environmental allergies, and expanding need for advanced diagnostic equipment for disease early identification and better monitoring.

Q.4. What are the major segments for eosinophilic esophagitis market?

Answer: The future of the eosinophilic esophagitis market looks promising with opportunities in the hospital, retail pharmacy, and online pharmacy markets.

Q.5. Who are the key eosinophilic esophagitis market companies?

Answer: Some of the key eosinophilic esophagitis companies are as follows:

  • Ellodi Pharmaceuticals
  • EsoCap
  • GlaxoSmithKline
  • Teva Pharmaceutical Industries
  • Cipla
  • Sun Pharmaceutical Industries
  • AstraZeneca
  • Sanofi
  • Arena Pharmaceuticals
  • Takeda Pharmaceutical

Q.6. Which eosinophilic esophagitis market segment will be the largest in future?

Answer: Lucintel forecasts that proton pump inhibitor is expected to witness highest growth over the forecast period due to its substantial application to reduce stomach acid production.

Q.7. In eosinophilic esophagitis market, which region is expected to be the largest in next 5 years?

Answer: North America is expected to witness highest growth over the forecast period.

Q.8. Do we receive customization in this report?

Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

  • Q.1. What are some of the most promising, high-growth opportunities for the eosinophilic esophagitis market by drug type (corticosteroids, proton pump inhibitor, and late stage pipeline drugs), end use (hospital, retail pharmacies, and online pharmacies), and region. (North America, Europe, Asia Pacific, and the Rest of the World)?
  • Q.2. Which segments will grow at a faster pace and why?
  • Q.3. Which region will grow at a faster pace and why?
  • Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
  • Q.5. What are the business risks and competitive threats in this market?
  • Q.6. What are the emerging trends in this market and the reasons behind them?
  • Q.7. What are some of the changing demands of customers in the market?
  • Q.8. What are the new developments in the market? Which companies are leading these developments?
  • Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
  • Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
  • Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Eosinophilic Esophagitis Market : Market Dynamics

  • 2.1: Introduction, Background, and Classifications
  • 2.2: Supply Chain
  • 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030

  • 3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
  • 3.2. Global Eosinophilic Esophagitis Market Trends (2018-2023) and Forecast (2024-2030)
  • 3.3: Global Eosinophilic Esophagitis Market by Drug Type
    • 3.3.1: Corticosteroids
    • 3.3.2: Proton Pump Inhibitor
    • 3.3.3: Late Stage Pipeline Drugs
  • 3.4: Global Eosinophilic Esophagitis Market by End Use
    • 3.4.1: Hospital
    • 3.4.2: Retail Pharmacies
    • 3.4.3: Online Pharmacies

4. Market Trends and Forecast Analysis by Region from 2018 to 2030

  • 4.1: Global Eosinophilic Esophagitis Market by Region
  • 4.2: North American Eosinophilic Esophagitis Market
    • 4.2.2: North American Eosinophilic Esophagitis Market by End Use: Hospital, Retail Pharmacies, and Online Pharmacies
  • 4.3: European Eosinophilic Esophagitis Market
    • 4.3.1: European Eosinophilic Esophagitis Market by Drug Type: Corticosteroids, Proton Pump Inhibitor, and Late Stage Pipeline Drugs
    • 4.3.2: European Eosinophilic Esophagitis Market by End Use: Hospital, Retail Pharmacies, and Online Pharmacies
  • 4.4: APAC Eosinophilic Esophagitis Market
    • 4.4.1: APAC Eosinophilic Esophagitis Market by Drug Type: Corticosteroids, Proton Pump Inhibitor, and Late Stage Pipeline Drugs
    • 4.4.2: APAC Eosinophilic Esophagitis Market by End Use: Hospital, Retail Pharmacies, and Online Pharmacies
  • 4.5: ROW Eosinophilic Esophagitis Market
    • 4.5.1: ROW Eosinophilic Esophagitis Market by Drug Type: Corticosteroids, Proton Pump Inhibitor, and Late Stage Pipeline Drugs
    • 4.5.2: ROW Eosinophilic Esophagitis Market by End Use: Hospital, Retail Pharmacies, and Online Pharmacies

5. Competitor Analysis

  • 5.1: Product Portfolio Analysis
  • 5.2: Operational Integration
  • 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

  • 6.1: Growth Opportunity Analysis
    • 6.1.1: Growth Opportunities for the Global Eosinophilic Esophagitis Market by Drug Type
    • 6.1.2: Growth Opportunities for the Global Eosinophilic Esophagitis Market by End Use
    • 6.1.3: Growth Opportunities for the Global Eosinophilic Esophagitis Market by Region
  • 6.2: Emerging Trends in the Global Eosinophilic Esophagitis Market
  • 6.3: Strategic Analysis
    • 6.3.1: New Product Development
    • 6.3.2: Capacity Expansion of the Global Eosinophilic Esophagitis Market
    • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Eosinophilic Esophagitis Market
    • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

  • 7.1: Ellodi Pharmaceuticals
  • 7.2: EsoCap
  • 7.3: GlaxoSmithKline
  • 7.4: Teva Pharmaceutical Industries
  • 7.5: Cipla
  • 7.6: Sun Pharmaceutical Industries
  • 7.7: AstraZeneca
  • 7.8: Sanofi
  • 7.9: Arena Pharmaceuticals
  • 7.10: Takeda Pharmaceutical